September 28, 2014 / 11:34 PM / 3 years ago

Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences

TOKYO (Reuters) - Japanese drugmaker Daiichi Sankyo Co Ltd (4568.T) has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp AMBI.O in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.

    The companies said in a joint statement that Daiichi Sankyo would acquire all outstanding common stock of San Diego-based Ambit Biosciences for $15 per share in cash through a tender offer, or about $315 million, and merge it with a subsidiary of Daiichi Sankyo. Ambit shares closed at $8.20 on Friday.

    Ambit Biosciences shareholders will also be eligible for an additional cash payment if certain milestones are reached, which would bring the total transaction to $410 million on a fully diluted basis, they said.

    Reporting by Chris Gallagher; Editing by Shri Navaratnam

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below